Advertisement


Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

2024 ASCO Annual Meeting

Advertisement

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Crystal-XII is a randomized phase three study that compare adagrasib with docetaxel in previously treated non-small cell lung cancer, that harbored KRAS-G2LC mutation. Now this study is important. Now, as you probably know, KRAS-G2LC accounted for about 14% of all lung adenocarcinoma. And then the adagrasib, which is a covalent bonded inhibitor of the KRAS-G2LC, as demonstrated in the early phase two data, that there is actually promising response rate, progression-free survival and over-survival. And also NCCN had approved that this is a category 2A agent for patient with this mutation, and brain metastasis. However, we still need to prove it with the randomized study, and is the time that we can share with you the result. So a bit of the design. This is designed to enroll the patient with the KRAS-G2LC stage four. The patient can receive chemotherapy, and also immunotherapy either concurrently or sequentially. It's a randomized in a two-to-one fashion, total above 453 patient. Now with that, there is actually, the patient actually was able to dispose, and majority of the patient received the targeted drug, meaning at aggressive of 99% of patient, and the dosage absolute arm is about 92% patient. And overall, the progression pre-survival is much improved, with the actually median of 5.5 versus, 3.8 months, hazard ratio 0.58. And also there is a difference in the response rate. 32% versus 9%, and this is also translated into a duration of response of about 8.4 months versus about 5.3 months. There's another feature that's important, which is the intracranial response. So for a patient with the known brain metastasis, we have a intracranial response rate of 24% versus about 11%. Safety wise, actually the most common toxicity is diarrhea. And then with this, actually the patient is mostly grade one and two. And also there's some nausea and vomiting, which is actually well controlled. One toxicity that's not so clear is that there's a slight elevation of the blood creatinine. However, most of this, patient will be reversible upon c-section of the drug. So as a conclusion, I think the Crystal-12 study had confirmed the role of the adagrasib as a second line therapy for patient with the lung cancer, with the KRAS-G2LC, after failing the chemotherapy and immunotherapy. In the future, there is also the Crystal-7 study, which actually put adagrasib in the first line. It will be in combination with pembrolizumab, comparing to pembrolizumab alone in patient with actually a PTPS score of over 50%.

Related Videos

Breast Cancer

Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 

Leukemia
Immunotherapy

Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment

Allison M. Winter, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses real-world outcomes with lisocabtagene maraleucel in patients with Richter transformation, a difficult-to-treat population with a poor prognosis. Data from the Center for International Blood and Marrow Transplant Research showed this therapy provided clinical benefit with a high complete response rate (Abstract 7010).

Skin Cancer

Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).

Advertisement

Advertisement




Advertisement